These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27468938)

  • 1. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.
    Reck M; Hagiwara K; Han B; Tjulandin S; Grohé C; Yokoi T; Morabito A; Novello S; Arriola E; Molinier O; McCormack R; Ratcliffe M; Normanno N
    J Thorac Oncol; 2016 Oct; 11(10):1682-9. PubMed ID: 27468938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating free tumor-derived DNA to detect
    Denis MG; Lafourcade MP; Le Garff G; Dayen C; Falchero L; Thomas P; Locher C; Oliviero G; Licour M; Reck M; Normanno N; Molinier O
    J Thorac Dis; 2019 Apr; 11(4):1370-1378. PubMed ID: 31179079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
    Arriola E; Paredes-Lario A; García-Gomez R; Diz-Tain P; Constenla M; García-Girón C; Márquez G; Reck M; López-Vivanco G
    Clin Transl Oncol; 2018 Oct; 20(10):1261-1267. PubMed ID: 29623586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.
    Han B; Tjulandin S; Hagiwara K; Normanno N; Wulandari L; Laktionov K; Hudoyo A; He Y; Zhang YP; Wang MZ; Liu CY; Ratcliffe M; McCormack R; Reck M
    Lung Cancer; 2017 Nov; 113():37-44. PubMed ID: 29110846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer.
    Ma M; Shi C; Qian J; Teng J; Zhong H; Han B
    Gene; 2016 Oct; 591(1):58-64. PubMed ID: 27370697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy.
    Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM
    Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
    Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
    J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.
    Prabhash K; Biswas B; Khurana S; Batra U; Biswas G; Advani SH; Mohapatra PN; Rajappa S; Sharma A; Patil S; Dattatreya PS; Roy R; Almel S; Goyal G; Warrier N
    Indian J Cancer; 2022 Mar; 59(Supplement):S11-S18. PubMed ID: 35343188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
    Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
    Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    Han JY; Choi JJ; Kim JY; Han YL; Lee GK
    BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
    Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
    Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.
    Normanno N; Denis MG; Thress KS; Ratcliffe M; Reck M
    Oncotarget; 2017 Feb; 8(7):12501-12516. PubMed ID: 27980215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis.
    Passiglia F; Rizzo S; Rolfo C; Galvano A; Bronte E; Incorvaia L; Listi A; Barraco N; Castiglia M; Calo V; Bazan V; Russo A
    Curr Cancer Drug Targets; 2018; 18(7):697-705. PubMed ID: 29521235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.
    Li Y; Xu H; Su S; Ye J; Chen J; Jin X; Lin Q; Zhang D; Ye C; Chen C
    PLoS One; 2017; 12(8):e0183331. PubMed ID: 28829813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer.
    Wan R; Wang Z; Lee JJ; Wang S; Li Q; Tang F; Wang J; Sun Y; Bai H; Wang D; Zhao J; Duan J; Zhuo M; An T; Wu M; Chen Z; Yang Z; Wang J
    J Thorac Oncol; 2017 Sep; 12(9):1376-1387. PubMed ID: 28552765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
    Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF
    Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study.
    Esteban E; Majem M; Martinez Aguillo M; Martinez Banaclocha N; Dómine M; Gómez Aldaravi L; Juan O; Cajal R; Gonzalez Arenas MC; Provencio M
    Cancer Epidemiol; 2015 Jun; 39(3):291-7. PubMed ID: 25766256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
    Reckamp KL; Melnikova VO; Karlovich C; Sequist LV; Camidge DR; Wakelee H; Perol M; Oxnard GR; Kosco K; Croucher P; Samuelsz E; Vibat CR; Guerrero S; Geis J; Berz D; Mann E; Matheny S; Rolfe L; Raponi M; Erlander MG; Gadgeel S
    J Thorac Oncol; 2016 Oct; 11(10):1690-700. PubMed ID: 27468937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.